SOX2 and prostate cancer: In non-small-cell lung cancer cells, SOX2 enhances the TGF-β-induced EMT process by negatively regulating TIF1γ expression.136 In breast and prostate cancer cells, SOX2 promotes EMT through the Wnt/β-catenin signaling pathway by directly binding to the β-catenin enhancer, therefore promoting tumor cell migration and invasion both in vitro and in vivo.131 In bladder cancer173 and lung cancer cells,174 SOX2 is required to act as an important bridge for FGFR/MAPK-induced EMT.